ClassID:

21089

A61K39/0291 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies; Bacterial antigens; Enterobacteriales, e.g. Enterobacter Yersinia

Recent Application in this class:
#1
20260014251
2026-01-15

COMPOSITIONS, METHODS, AND USES FOR POLYNUCLEOTIDE FORMULATIONS FOR DRYING AND PROLONGED STORAGE

#2
20250360190
2025-11-27

IMMUNOGENICITY OF A CPG-ADJUVANTED RECOMBINANT PLAGUE VACCINE

#3
20250275922
2025-09-04

THERMOSTABLE PARTICLE-BASED COMPOSITIONS AND MANUFACTURING PROCESS

#4
20250223319
2025-07-10

IMPROVED CHIMERIC POLYPEPTIDES AND USES THEREOF

#5
20250177534
2025-06-05

THERMOSTABLE UV INACTIVATED VACCINES AND OTHER BIOPHARMACEUTICALS

#6
20250177515
2025-06-05

METHODS AND COMPOSITIONS RELATING TO IMMUNIZATION OF IMMUNE DISTINCT PATIENTS

#7
20250152694
2025-05-15

METHODS AND COMPOSITIONS FOR MULTIVALENT VACCINES

#8
20250134981
2025-05-01

SELF-ADJUVANTING YERSINIA OUTER MEMBRANE VESICLE AS A VACCINE AGAINST PLAGUE, ANTHRAX AND PSEUDOMONAS INFECTION

#9
20240335518
2024-10-10

GUT BACTERIA DERIVED MICROVESICLES FOR VACCINE DELIVERY

#10
20240252610
2024-08-01

A BROADLY PROTECTIVE PROPHYLACTIC VACCINE AGAINST PSEUDOMONAS AERUGINOSA

#11
20240165215
2024-05-23

IMMUNOGENICITY OF A CPG-ADJUVANTED RECOMBINANT PLAGUE VACCINE

#12
20230112697
2023-04-13

METHODS AND COMPOSITIONS RELATED TO THE NEXT GENERATION VACCINE

#13
20220280628
2022-09-08

Self-adjuvanting outer membrane vesicle as a vaccine against plague, anthrax and pseudomonas infection

#14
20220105168
2022-04-07

Gut bacteria derived microvesicles for vaccine delivery

#15
20220054585
2022-02-24

IMMUNOMODULATORY & ONCOLYTIC MINICELLS AND METHODS OF USE

#16
20210381015
2021-12-09

Immunotherapeutic potential of modified lipooligosaccharides/lipid A

#17
20210252127
2021-08-19

Methods and compositions related to the next generation vaccine

#18
20210213129
2021-07-15

NON-PSYCHOACTIVE CANNABINOIDS AS ADJUVANTS TO ENHANCE MUCOSAL IMMUNITY

#19
20210177956
2021-06-17

Self-adjuvanting yersinia outer membrane vesicle as a vaccine against plague, anthrax and pseudomonas infection

#20
20210052715
2021-02-25

Immunomodulatory minicells and methods of use

#21
20200331949
2020-10-22

D-glycero-B-D-heptose 1-phosphate (HMP) conjugates and use for targeted immune modulation

#22
20200282048
2020-09-10

Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response

#23
20200147207
2020-05-14

Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, bacillus anthracis and yersinia pestis

#24
20190367959
2019-12-05

Immunotherapeutic potential of modified lipooligosaccharides/lipid A

#25
20190240310
2019-08-08

Safe potent single platform vaccine against Tier 1 select agents and other pathogens

#26
20190167778
2019-06-06

Immunomodulatory minicells and methods of use

#27
20190015497
2019-01-17

Virulence attenuated bacteria for treatment of malignant solid tumors

#28
20180360953
2018-12-20

METHODS TO IMPROVE INDUCTION OF IGG AND IGA ANTIBODIES BY VACCINES

#29
20180264102
2018-09-20

Dual anthrax-plague vaccines that can protect against two tier-1 bioterror pathogens, and

#30
20180140665
2018-05-24

Immunomodulatory and oncolytic minicells and methods of use

#31
20180099043
2018-04-12

Methods to improve induction of IgA antibodies by vaccines

#32
20170296644
2017-10-19

Methods for treating plague

#33
20170281755
2017-10-05

Oral administration of at least one pharmaceutical and/or antigenic active substance

#34
20160339095
2016-11-24

Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens

#35
20160228527
2016-08-11

spp. polypeptides and methods of use

#36
20160199475
2016-07-14

Live-attenuated vaccine against plague

#37
20160158334
2016-06-09

Immunomodulatory minicells and methods of use

#38
20160089427
2016-03-31

Genetically modified as vaccines against species

#39
20160051655
2016-02-25

spp. polypeptides and methods of use

#40
20160002691
2016-01-07

Immunotherapeutic potential of modified lipooligosaccharides/lipid A

#41
20150343046
2015-12-03

COMPOSITIONS, METHODS AND USES FOR EXPRESSION OF ENTEROBACTERIUM-ASSOCIATED PEPTIDES

#42
20150307598
2015-10-29

spp. polypeptides and methods of use

#43
20150216959
2015-08-06

Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens

#44
20150202275
2015-07-23

Plague vaccine

#45
20150152144
2015-06-04

typhi Ty21a expressing F1-V fusion protein and uses thereof

#46
20150050318
2015-02-19

MULTIVALENT NANOEMULSION VACCINES

#47
20150050312
2015-02-19

Bacterial vaccine

#48
20150050311
2015-02-19

NOVEL METHOD FOR THE PREPARATION OF A STRAIN-ADAPTED VACCINE

#49
20150030632
2015-01-29

Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen

#50
20150017198
2015-01-15

Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from as next generation plague vaccines

#51
20140328880
2014-11-06

Modified pathogens for use as vaccines

#52
20140294895
2014-10-02

Expression of Protective Antigens in Transgenic Chloroplasts and the Production of Improved Vaccines

#53
20140170164
2014-06-19

spp. polypeptides and methods of use

#54
20140161838
2014-06-12

spp. polypeptides and methods of use

#55
20140161834
2014-06-12

spp. polypeptides and methods of use

#56
20140120128
2014-05-01

Use of YSCF, truncated YSCF and YSCF homologs as adjuvants

#57
20140004150
2014-01-02

Vaccine injection, preparation method and use thereof

#58
20130273092
2013-10-17

USES OF YERSINIA YOPE PEPTIDE, GENE AND SUBPARTS THEREOF AS A PLAGUE VACCINE COMPONENT AND ASSAYS FOR YERSINIA PESTIS-SPECIFIC T CELLS

#59
20130189308
2013-07-25

EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES

#60
20130149327
2013-06-13

antigens, vaccine compositions, and related methods

#61
20130034583
2013-02-07

Compositions, methods and uses for expression of enterobacterium-associated peptides

#62
20120258137
2012-10-11

IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND HEPATITIS B VIRUS IMMUNOGEN AND METHODS OF USING THE SAME

#63
20120135038
2012-05-31

EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES

#64
20120107349
2012-05-03

Multivalent nanoemulsion vaccines

#65
20110256177
2011-10-20

vaccine

#66
20110206674
2011-08-25

Yersinia SPP. Polypeptides and Methods of Use

#67
20110159047
2011-06-30

STABLE POWDER FORMULATIONS OF ALUM-ADSORBED VACCINES

#68
20110033494
2011-02-10

Anti-infective agents and uses thereof

#69
20110027304
2011-02-03

antigens, vaccine compositions, and related methods

#70
20100285048
2010-11-11

Use of flagellin in the immunotherapy of

#71
20100209451
2010-08-19

Compositions and Methods Related to Adenovirus Based Delivery of Antigens

#72
20100112002
2010-05-06

Modified pathogens for use as vaccines

#73
20100028433
2010-02-04

Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same

#74
20080226729
2008-09-18

STABLE POWDER FORMULATIONS OF ALUM-ADSORBED VACCINES

#75
20080220011
2008-09-11

Use of Flagellin in Tumor Immunotherapy

#76
20080124361
2008-05-29

Use of flagellin in the immunotherapy of

#77
20070087013
2007-04-19

Orally-administered live bacterial vaccines for plague

#78
20060269564
2006-11-30

spp. polypeptides and methods of use

#79
20060045888
2006-03-02

Antigen library immunization

#80
20050108792
2005-05-19

Expression of protective antigens in transgenic chloroplasts

#81
14822178
2019-01-08

Multivalent DNA composition for